Latest News and Press Releases

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar...

New York, USA, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Hidradenitis Suppurativa Market to Showcase Remarkable Growth at a CAGR of 12.4% by 2034 | DelveInsight  According to DelveInsight’s analysis, the...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable...

Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)Initiation of...

Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential...

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions  MoonLake to tap into Komodo’s technology and...

Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as...

NEW YORK, Dec. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and...